Coherus, Junshi’s PD-1 blocker Loqtorzi aces phase III liver cancer trial

Coherus BioSciences and Junshi Biosciences’ PD-1 inhibitor Loqtorzi significantly boosted progression-free and overall survival in a late-stage study of patients with advanced hepatocellular carcinoma.